-
Mashup Score: 21Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC - 1 month(s) ago
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion, exon 21 L858R), osimertinib remains the standard of care approved by the U.S. Food and Drug Administration in the first-line treatment of EGFR-mutated, advanced NSCLC. Despite continued efforts, disease progression remains inevitable with a high incidence of brain metastasis and poor prognosis for the patients harboring L858R.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC - 2 month(s) ago
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion, exon 21 L858R), osimertinib remains the standard of care approved by the U.S. Food and Drug Administration in the first-line treatment of EGFR-mutated, advanced NSCLC. Despite continued efforts, disease progression remains inevitable with a high incidence of brain metastasis and poor prognosis for the patients harboring L858R.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC - 2 month(s) ago
“Don’t be afraid to give up the good to go for the great.”John D. Rockefeller
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
Controversies in #LungCancer: Here are the reasons why some researchers and clinicians believe that the combination of chemotherapy and osimertinib should not be the first-line treatment for all advanced #EGFR+ #NSCLC. https://t.co/zY06WUERwe #LCSM https://t.co/sAJpGa0mp2